Bio-Rad Laboratories Inc. (BIO)’s Financial Results Comparing With NeoGenomics Inc. (NASDAQ:NEO)

Bio-Rad Laboratories Inc. (NYSE:BIO) and NeoGenomics Inc. (NASDAQ:NEO) compete with each other in the Medical Laboratories & Research sector. We will analyze and contrast their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bio-Rad Laboratories Inc. 2.29B 3.40 1.28B 39.78 6.33
NeoGenomics Inc. 280.05M 5.81 7.14M 0.05 273.33

Table 1 demonstrates Bio-Rad Laboratories Inc. and NeoGenomics Inc.’s gross revenue, earnings per share (EPS) and valuation. NeoGenomics Inc. is observed to has lower revenue and earnings than Bio-Rad Laboratories Inc. Business that presently has a lower price-to-earnings ratio means that it is the more affordable of the two businesses. Bio-Rad Laboratories Inc.’s current price-to-earnings ratio is lower than that of NeoGenomics Inc., which means that it is the affordable of the two.

Profitability

Table 2 demonstrates the return on equity, net margins and return on assets of Bio-Rad Laboratories Inc. and NeoGenomics Inc.

Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories Inc. 55.90% 30% 21.6%
NeoGenomics Inc. 2.55% 3.9% 2.1%

Volatility and Risk

Bio-Rad Laboratories Inc. is 10.00% more volatile than Standard and Poor’s 500 because the stock has a beta of 1.1. In other hand, NeoGenomics Inc. has beta of 0.07 which is 93.00% less volatile than Standard and Poor’s 500.

Liquidity

Bio-Rad Laboratories Inc.’s Current Ratio is 4.5 while its Quick Ratio is 3.2. On the competitive side is, NeoGenomics Inc. which has a 4.1 Current Ratio and a 4 Quick Ratio. Bio-Rad Laboratories Inc. is better positioned to pay off short and long-term obligations compared to NeoGenomics Inc.

Analyst Recommendations

The Ratings and Recommendations for Bio-Rad Laboratories Inc. and NeoGenomics Inc. are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Bio-Rad Laboratories Inc. 0 1 2 2.67
NeoGenomics Inc. 0 0 3 3.00

Bio-Rad Laboratories Inc. has a 27.33% upside potential and a consensus target price of $333.33. NeoGenomics Inc. on the other hand boasts of a $17.67 average target price and a 2.55% potential upside. The information presented earlier suggests that Bio-Rad Laboratories Inc. looks more robust than NeoGenomics Inc. as far as analyst opinion.

Insider and Institutional Ownership

Roughly 77.4% of Bio-Rad Laboratories Inc. shares are held by institutional investors while 83.2% of NeoGenomics Inc. are owned by institutional investors. Insiders held 1.9% of Bio-Rad Laboratories Inc. shares. Comparatively, 2.8% are NeoGenomics Inc.’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Bio-Rad Laboratories Inc. -8.29% -11.11% -18.28% -16.38% -1.28% 5.46%
NeoGenomics Inc. -15% -22.56% 4.81% 7.56% 52.35% 57.34%

For the past year Bio-Rad Laboratories Inc.’s stock price has smaller growth than NeoGenomics Inc.

Summary

Bio-Rad Laboratories Inc. beats NeoGenomics Inc. on 11 of the 15 factors.

Bio-Rad Laboratories, Inc. manufactures and supplies products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls that serve clinical laboratories in the diagnostics market. Its products include reagents, instruments, and software which address specific niches within the in vitro diagnostics (IVD) test market. This segment sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. It operates in Europe, Pacific Rim, the United States, and internationally. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clientsÂ’ oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.